In this article, we will list the 5 best stocks to invest in according to Jim Simons’ Renaissance Technologies. Please visit 12 Best Stocks to Invest In According to Jim Simons’ Renaissance Technologies if you would like to see the extended list and the methodology behind it.

5. Micron Technology, Inc. (NASDAQ:MU)

Renaissance Technologies’ Stake: $731 Million

Micron Technology, Inc. (NASDAQ:MU) has featured intermittently in the 13F portfolio of Renaissance Technologies. The fund first disclosed a stake in the company back in the first quarter of 2011. This position comprised 1.7 million shares and was sold off entirely by the next quarter. Since then, the fund has bought a stake in the company many times and sold it off within a few months. The latest holding was purchased in the third quarter of 2025. It comprised 1.2 million shares at the time. Filings for the first quarter of 2026 show that the fund owned 2.1 million shares in the firm, down nearly 30% compared to filings for the previous quarter.

Micron Technology (NASDAQ:MU) shattered Wall Street expectations in the latest earnings report. The firm pulled in $23.86 billion in Q2 2026 revenue, representing a 196% surge year-over-year, nearly tripling the $8.05 billion recorded in Q2 2025, and a 75% sequential jump from Q1. Non-GAAP diluted EPS landed at $12.20, obliterating the Wall Street consensus estimate of $8.60 by 41.8%. For comparison, EPS in the same quarter last year was just $1.56. Fueled by a supply deficit that sent average selling prices (ASPs) soaring, non-GAAP gross margin expanded to 74.9%, up 18 percentage points sequentially.

4. Kinross Gold Corporation (NYSE:KGC)

Renaissance Technologies’ Stake: $780 Million

Kinross Gold Corporation (NYSE:KGC) has been a consistent feature in the 13F portfolio of Renaissance Technologies for many years. The fund first disclosed a stake in the company back in the first quarter of 2011. This position comprised 448,000 shares. The fund sold off this holding within months. A new position in the company was then declared in the second quarter of 2013. Since then, the firm has featured constantly in the portfolio of the fund. Filings for the first quarter of 2026 show that the fund owned more than 25 million shares in the company, up more than 2% compared to filings for the fourth quarter of 2025.

The bull case for Kinross Gold Corporation (NYSE:KGC) centers on the operating leverage it is capturing as gold trades at historically elevated prices. When revenue expands faster than unit costs, the translation to the bottom line is explosive. Driven by an extraordinary average realized gold price of $4,873 per ounce in Q1, metal sales in the latest earnings rose 61% year-over-year to $2.41 billion, up from $1.50 billion in Q1 2025. Adjusted net earnings skyrocketed to $854.1 million, or $0.71 per share, more than doubling the $0.30 per share reported in the prior-year period. Despite facing inflationary operational cost pressures, production margins increased by 92% year-over-year to a record $3,476 per gold equivalent ounce sold, comfortably outpacing cost increases.

3. Apple Inc. (NASDAQ:AAPL)

Renaissance Technologies’ Stake: $781 Million

Apple Inc. (NASDAQ:AAPL) has featured intermittently in the 13F portfolio of Renaissance Technologies. The fund first disclosed a stake in the company back in the fourth quarter of 2010. This position comprised 38 million shares. By early 2013, this stake had been sold off completely. Since then, the fund has purchased many stakes in the company and sold them off after holding them for a relatively short period of time. Filings for the first quarter of 2026 show that the fund has purchased a new stake in the company. This position comprises more than 3 million shares, the latest data shows.

READ ALSO: Lone Pine’s Non-AI Strategy Falters: 10 Non-AI Stocks Weighing Down Stephen Mandel’s 2026 Returns.

Critics frequently worry about smartphone stagnation, but the hardware engine of Apple Inc. (NASDAQ:AAPL) continues to show pricing leverage and demand. For Q2 2026, iPhone revenue hit a March-quarter record of $56.99 billion, surging 22% year-over-year. This growth was primarily driven by demand for the iPhone 17 lineup and new form factors like the iPhone 17e. Despite widespread fears of a slowdown in Asian markets, Apple posted double-digit revenue growth across every single geographic segment. Notably, sales in Greater China rebounded sharply, jumping 28% year-over-year to reach $20.5 billion. Services revenue reached an all-time high of $30.98 billion in Q2 2026, posting 16% year-over-year growth.

2. Palantir Technologies Inc. (NASDAQ:PLTR)

Renaissance Technologies’ Stake: $1 Billion

Palantir Technologies Inc. (NASDAQ:PLTR) is a relatively recent addition to the 13F portfolio of Renaissance Technologies. The fund first disclosed a stake in the company back in the second quarter of 2021. This position comprised 800,000 shares. The fund steadily built onto this stake in the coming quarters, increasing it to more than 47 million shares by early 2024. Thereafter, it trimmed the holding. Filings for the first quarter of 2026 show that the fund owned just under 7 million shares in the company, down over 20% compared to filings for the previous quarter.

The core of the bull case for Palantir Technologies Inc. (NASDAQ:PLTR) relies on the Artificial Intelligence Platform (AIP) and the unique bootcamp go-to-market strategy, which allows enterprises to build operational AI workflows in days rather than months. In Q1 2026, US Commercial revenue jumped by 133% year-over-year to $595 million. Total commercial customers scaled to 1,007 on a trailing basis, growing 31% year-over-year. Trailing 12-month US commercial Total Contract Value (TCV) bookings reached $4.7 billion, a 115% increase compared to the prior 12-month period. US Government revenue grew 84% year-over-year to $687 million in Q1 2026. This represents an acceleration from the 66% growth one quarter prior.

1. United Therapeutics Corporation (NASDAQ:UTHR)

Renaissance Technologies’ Stake: $1.1 Billion

United Therapeutics Corporation (NASDAQ:UTHR) is a long-term holding in the 13F portfolio of Renaissance Technologies. The fund first disclosed a stake in the company back in the fourth quarter of 2010. This position comprised 261,000 shares. By the middle of 2012, this position had been sold off completely. A new position in the company was then opened in the fourth quarter of 2014. Since then, the stock has featured consistently in the portfolio of the fund. Filings for the first quarter of 2026 show that the fund owned just under 1.8 million shares in the firm, down more than 6% compared to filings for the fourth quarter of 2025.

United Therapeutics Corporation (NASDAQ:UTHR) is expanding into Idiopathic Pulmonary Fibrosis (IPF), a progressive, fatal lung disease with almost no effective treatments. Following the blockbuster success of the Phase 3 TETON-2 study, the latest clinical data from the TETON studies showed that nebulized Tyvaso achieved highly significant improvements in lung function over 52 weeks. Management noted that physicians are highly impressed with the TETON data, and the company is preparing major NDA submissions to the FDA. If approved, Tyvaso will be the first inhaled anti-fibrotic treatment for IPF.

READ NEXT: Growth Stock Portfolio: 12 Stock Picks by Carl C. Icahn and Chris Rokos Stock Portfolio: Top 10 Stock Picks.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.